Clinical Data, Inc. To Present at the MedImpact Healthcare Systems 2008 Annual Conference in San Diego
Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that its Chief Medical Officer, Carol Reed, MD, will participate at a conference sponsored by MedImpact Healthcare Systems on “Changing Tides in Health Care.” The conference is being held on February 20-22, 2008 at The Hotel Del Coronado in San Diego, California.
Dr. Reed’s presentation, “The Value of Pharmacogenetic Testing,” which starts at 1:00pm PT today, February 21, will focus on the value of individualizing drug treatment based on a patient’s genetics. Numerous examples now demonstrate that pharmacogenetic tests can add value by predicting an individual patient’s response to a given drug and the likelihood of side effects in that patient. This has positive and far reaching implications for patients, providers and payers.
Dr. Reed will also review the challenges facing the healthcare industry with respect to drug efficacy and side effects, the status of pharmacogenetic tests designed to predict drug response and side effects in individuals, and how caregivers and payers are incorporating these tests into clinical care practices. This presentation will include a review of Clinical Data’s FAMILION™ tests for cardiac channelopathies and PGx Predict™ test for Warfarin dosing. Dr. Reed will conclude with remarks on what payors and providers should be doing to stay current with pharmacogenetic advances and to maximize their impact on the delivery of healthcare.
About MedImpact Healthcare Systems, Inc.
MedImpact Healthcare Systems, Inc., based in San Diego, California, was founded in 1989. The company currently serves 29 million individuals nationwide with clients that include Fortune 500 corporations and large employers, unions, managed care organizations, insurance carriers, third-party administrators, as well as local, state and federal employee programs. MedImpact bases its success on delivering innovative products and services designed to lower overall client cost while increasing member satisfaction and quality of care. For more information on MedImpact, please visit www.medimpact.com.
About PGxHealth™
PGxHealth is a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers. This division of Clinical Data has extensive experience and capabilities in the development, clinical validation and delivery of genetic tests that assist providers in targeting efficacious and safe drugs for their patients. PGxHealth also leverages its capabilities and intellectual property to develop therapeutics which are targeted at patient subpopulations where drug response is enhanced. Through its know-how and resources, work conducted with some of the world’s most prestigious genomics thought leaders and institutions, and use of innovative technologies, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in those disease states and therapeutic classes beset with expensive, inefficient or suboptimal treatment options. It has branded its genetic tests based on these proprietary genetic markers as Therapeutic Diagnostics™. For more information about PGxHealth, please visit its website at www.pgxhealth.com.
About Clinical Data, Inc.
Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare™. Its PGxHealth™ division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics™ division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company’s website at www.clda.com for more information.